Janux Therapeutics (JANX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $16.51, -4.68% vs the prior close of $17.32.
- Volume 765.88K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
JANX slides 4.7% to $16.51. Closed at $16.51, -4.68% vs the prior close of $17.32. Day range $16.43–$17.27, opened at $17.27.
JANX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — JANX slides 4.7% to $16.51
- Closed at $16.51, -4.68% vs the prior close of $17.32. Day range $16.43–$17.27, opened at $17.27.
- Volume was 765.88K shares, 0.9x its 50-day average of 874.68K.
- Price is -5.5% vs its 50-day average ($17.47) and +8.9% vs its 200-day average ($15.16).
- 52-week range $12.12–$35.34; today's close sits at 19% of that range, 53.3% below the 52-week high.
Oct 15, 2026 — JANX rises 1.1% to $17.32
- Closed at $17.32, +1.11% vs the prior close of $17.13. Day range $17.02–$17.62, opened at $17.30.
- Volume was 546.90K shares, 0.6x its 50-day average of 874.66K.
- Price is -0.8% vs its 50-day average ($17.46) and +14.3% vs its 200-day average ($15.15).
- 52-week range $12.12–$35.34; today's close sits at 22% of that range, 51.0% below the 52-week high.
Oct 14, 2026 — JANX ends flat (-0.3%) to $17.13, 4 down days in a row
- Closed at $17.13, -0.29% vs the prior close of $17.18. Day range $16.84–$17.49, opened at $17.13.
- Volume was 614.60K shares, 0.7x its 50-day average of 873.66K.
- Price is -1.8% vs its 50-day average ($17.44) and +13.2% vs its 200-day average ($15.13).
- 52-week range $12.12–$35.34; today's close sits at 22% of that range, 51.5% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — JANX slides 5.3% to $17.18, 3 down days in a row
- Closed at $17.18, -5.34% vs the prior close of $18.15. Day range $16.97–$18.14, opened at $18.06.
- Volume was 794.90K shares, 0.9x its 50-day average of 868.94K.
- Price is -1.3% vs its 50-day average ($17.41) and +13.6% vs its 200-day average ($15.12).
- 52-week range $12.12–$35.34; today's close sits at 22% of that range, 51.4% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — JANX dips 1.3% to $18.15
- Closed at $18.15, -1.31% vs the prior close of $18.39. Day range $17.96–$18.60, opened at $18.29.
- Volume was 803.00K shares, 0.9x its 50-day average of 863.09K.
- Price is +4.5% vs its 50-day average ($17.38) and +20.2% vs its 200-day average ($15.10).
- 52-week range $12.12–$35.34; today's close sits at 26% of that range, 48.6% below the 52-week high.
Oct 9, 2026 — JANX dips 0.6% to $18.39
- Closed at $18.39, -0.59% vs the prior close of $18.50. Day range $18.32–$19.18, opened at $18.42.
- Volume was 1.17M shares, 1.4x its 50-day average of 853.44K.
- Price is +6.2% vs its 50-day average ($17.32) and +21.9% vs its 200-day average ($15.08).
- 52-week range $12.12–$35.34; today's close sits at 27% of that range, 48.0% below the 52-week high.
Oct 8, 2026 — JANX jumps 3.2% to $18.50, 3 up days in a row
- Closed at $18.50, +3.24% vs the prior close of $17.92. Day range $17.30–$18.90, opened at $17.77.
- Volume was 1.50M shares, 1.8x its 50-day average of 835.48K.
- Price is +7.2% vs its 50-day average ($17.26) and +22.8% vs its 200-day average ($15.06).
- 52-week range $12.12–$35.34; today's close sits at 27% of that range, 47.7% below the 52-week high.
- That makes 3 straight gains.
Oct 7, 2026 — JANX jumps 6.7% to $17.92
- Closed at $17.92, +6.73% vs the prior close of $16.79. Day range $16.42–$18.36, opened at $16.52.
- Volume was 1.21M shares, 1.5x its 50-day average of 824.97K.
- Price is +4.3% vs its 50-day average ($17.19) and +19.2% vs its 200-day average ($15.04).
- 52-week range $12.12–$35.34; today's close sits at 25% of that range, 49.3% below the 52-week high.
Oct 6, 2026 — JANX rises 1.5% to $16.79
- Closed at $16.79, +1.51% vs the prior close of $16.54. Day range $16.31–$17.37, opened at $16.69.
- Volume was 809.80K shares, 1.0x its 50-day average of 836.68K.
- Price is -2.0% vs its 50-day average ($17.13) and +11.8% vs its 200-day average ($15.02).
- 52-week range $12.12–$35.34; today's close sits at 20% of that range, 52.5% below the 52-week high.
Oct 5, 2026 — JANX dips 2.3% to $16.54, 3 down days in a row
- Closed at $16.54, -2.30% vs the prior close of $16.93. Day range $16.13–$16.95, opened at $16.93.
- Volume was 533.70K shares, 0.6x its 50-day average of 837.01K.
- Price is -3.3% vs its 50-day average ($17.11) and +10.2% vs its 200-day average ($15.00).
- 52-week range $12.12–$35.34; today's close sits at 19% of that range, 53.2% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — JANX ends flat (-0.2%) to $16.93
- Closed at $16.93, -0.18% vs the prior close of $16.96. Day range $16.83–$17.29, opened at $17.25.
- Volume was 805.30K shares, 1.0x its 50-day average of 839.53K.
- Price is -0.9% vs its 50-day average ($17.08) and +12.9% vs its 200-day average ($14.99).
- 52-week range $12.12–$35.34; today's close sits at 21% of that range, 52.1% below the 52-week high.
JANX latest news & SEC filings
Every SEC filing by or about JANX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$21.97M (prior year -$33.86M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.35 (prior year -$0.55) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 28, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade JANX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.45% (largest 6.7%).
- Liquidity: about 837.62K shares (≈$13.83M) trade per day on average.
- 52-week position: $16.51 vs a range of $12.12–$35.34 (19% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Janeen Noel Doyle sold 4,059 shares on Jun 2, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jun 23, 2026.
- Share count: 61.14M shares outstanding (Aug 4, 2026), +1.7% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
JANX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 17.27 | 17.27 | 16.43 | 16.51 | 765.88K |
| Oct 15, 2026 | 17.30 | 17.62 | 17.02 | 17.32 | 546.90K |
| Oct 14, 2026 | 17.13 | 17.49 | 16.84 | 17.13 | 614.60K |
| Oct 13, 2026 | 18.06 | 18.14 | 16.97 | 17.18 | 794.90K |
| Oct 12, 2026 | 18.29 | 18.60 | 17.96 | 18.15 | 803.00K |
| Oct 9, 2026 | 18.42 | 19.18 | 18.32 | 18.39 | 1.17M |
| Oct 8, 2026 | 17.77 | 18.90 | 17.30 | 18.50 | 1.50M |
| Oct 7, 2026 | 16.52 | 18.36 | 16.42 | 17.92 | 1.21M |
| Oct 6, 2026 | 16.69 | 17.37 | 16.31 | 16.79 | 809.80K |
| Oct 5, 2026 | 16.93 | 16.95 | 16.13 | 16.54 | 533.70K |
| Oct 2, 2026 | 17.25 | 17.29 | 16.83 | 16.93 | 805.30K |
| Oct 1, 2026 | 17.20 | 17.35 | 16.76 | 16.96 | 837.50K |
| Sep 30, 2026 | 17.08 | 17.56 | 16.79 | 17.28 | 772.50K |
| Sep 29, 2026 | 16.54 | 16.98 | 16.32 | 16.95 | 511.70K |
| Sep 28, 2026 | 16.57 | 16.79 | 16.16 | 16.58 | 473.00K |
| Sep 25, 2026 | 16.62 | 16.70 | 16.21 | 16.30 | 720.20K |
| Sep 24, 2026 | 16.42 | 16.79 | 15.75 | 16.68 | 1.30M |
| Sep 23, 2026 | 17.40 | 17.47 | 16.34 | 16.52 | 967.40K |
| Sep 22, 2026 | 17.17 | 17.47 | 16.97 | 17.47 | 908.30K |
| Sep 21, 2026 | 16.86 | 17.14 | 16.53 | 17.01 | 701.80K |
About Janux Therapeutics
Janux Therapeutics (JANX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1817713.
JANX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Ronald W Barrett | Director | Jun 12, 2026 |
| Vickie L Capps | Director | Jun 12, 2026 |
| David Alan Campbell | President and CEO | Jul 31, 2026 |
| Eric Dobmeier | Director | Jun 12, 2026 |
| Natasha Hernday | Director | Jun 12, 2026 |
| Peter Kolchinsky | Director | Jun 12, 2026 |
| Winston Kung | Director | Jun 12, 2026 |
| Capital Management, L.P. Ra | Director | Jun 12, 2026 |
| Capital Healthcare Fund Lp Ra | Director | Jun 12, 2026 |
| Capital Nexus Fund Ii, L.P. Ra | Director | Jun 12, 2026 |
| Rajeev M. Shah | Director | Jun 12, 2026 |
| Jake Simson | Director | Jun 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| David Alan Campbell | President and CEO | Jul 31, 2026 |
| Thomas Diraimondo | Chief Scientific Officer | Jan 2, 2026 |
| Maria Dobek | Vice President, Accounting | May 13, 2026 |
| Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | Jun 4, 2026 |
| William Go | Chief Medical Officer | Feb 4, 2026 |
| Zachariah Mciver | Chief Medical Officer | Jan 2, 2026 |
| Andrew Hollman Meyer | Chief Business Officer | Jan 2, 2026 |
| Charles M. Winter | Chief Technical Officer | Jan 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 2, 2026 | Janeen Noel Doyle | Sale | 4,059 | $14.03 |
| Jun 2, 2026 | Janeen Noel Doyle | Sale | 4,059 | $14.03 |
| Jun 2, 2026 | Janeen Noel Doyle | Sale | 4,059 | $14.03 |
| Jun 2, 2026 | Janeen Noel Doyle | Sale | 4,059 | $14.03 |
| May 11, 2026 | Maria Dobek | Sale | 2,038 | $14.17 |
| May 11, 2026 | Maria Dobek | Sale | 2,038 | $14.17 |
| May 11, 2026 | Maria Dobek | Sale | 2,038 | $14.17 |
| May 11, 2026 | Maria Dobek | Sale | 2,038 | $14.17 |
| Jan 2, 2026 | Thomas Diraimondo | Sale | 2,505 | $13.73 |
| Jan 2, 2026 | Thomas Diraimondo | Sale | 2,505 | $13.73 |
| Jan 2, 2026 | Thomas Diraimondo | Sale | 2,505 | $13.73 |
| Jan 2, 2026 | Thomas Diraimondo | Sale | 2,505 | $13.73 |
| Jan 2, 2026 | Zachariah Mciver | Sale | 2,714 | $13.73 |
| Jan 2, 2026 | Zachariah Mciver | Sale | 2,714 | $13.73 |
| Jan 2, 2026 | Zachariah Mciver | Sale | 2,714 | $13.73 |
JANX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-113.62M | -1.83 | $-82.23M |
| Dec 31, 2024 | — | $-68.99M | -1.28 | $-43.81M |
| Dec 31, 2023 | — | $-58.29M | -1.32 | $-50.58M |
| Dec 31, 2022 | — | $-63.06M | -1.52 | $-42.92M |
| Dec 31, 2021 | — | $-32.67M | -1.39 | $-16.98M |
Latest balance sheet: total assets $1.01B, total liabilities $79.67M, cash $27.77M (as of Jun 30, 2026).
JANX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $16.10 |
| May 7, 2026 | 8-K Item 2.02 (results) | $14.54 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $13.80 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $28.66 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $22.58 |
| May 8, 2025 | 8-K Item 2.02 (results) | $26.37 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $32.01 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $54.89 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Mar 8, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on JANX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.